BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11404464)

  • 1. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome.
    Wong AK; Alfert M; Castrillon DH; Shen Q; Holash J; Yancopoulos GD; Chin L
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7481-6. PubMed ID: 11404464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.
    Yoshiji H; Kuriyama S; Ways DK; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Tsujinoue H; Nakatani T; Shibuya M; Fukui H
    Cancer Res; 1999 Sep; 59(17):4413-8. PubMed ID: 10485491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vascular endothelial growth factor in the regulation of angiogenesis.
    Ferrara N
    Kidney Int; 1999 Sep; 56(3):794-814. PubMed ID: 10469350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
    Avramis IA; Kwock R; Avramis VI
    Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
    Graff BA; Bjørnaes I; Rofstad EK
    Microvasc Res; 2001 Mar; 61(2):187-98. PubMed ID: 11254398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
    Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
    Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
    Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.
    Kim ES; Serur A; Huang J; Manley CA; McCrudden KW; Frischer JS; Soffer SZ; Ring L; New T; Zabski S; Rudge JS; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11399-404. PubMed ID: 12177446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanisms of hepatic sinusoidal endothelial cell regeneration: a possible communication system associated with vascular endothelial growth factor in liver cells.
    Mochida S; Ishikawa K; Toshima K; Inao M; Ikeda H; Matsui A; Shibuya M; Fujiwara K
    J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S1-5. PubMed ID: 9792028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].
    Wang F; Tian YH; Li L; Chen XF; Hu HH; Li CY; Huang Q
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Mar; 34(2):165-70. PubMed ID: 12006990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.